By Rob Trotter
CBG is one of several cannabinoids in marijuana that has yet to be fully examined by the medical community. Here at the Pot Zero Plantation in Gypsum, CO we are very fortunate that our crop in 2017 exhibited high levels of CBG. We believe this was due to the stress of two major early blizzards and extreme light deprivation and temperature fluctuations, along with other environmental conditions. Typically, marijuana contains levels of CBG below 1%, as CBG converts to CBD and THC during a plant’s normal life cycle. However, we have CBG in all of our strains of 2-4% and when concentrated, our CBG levels are 6-7 percent. We are very fortunate that the CBG in our plants is FAR ABOVE AVERAGE. This high level of CBG makes for a particularly interesting high without paranoia and very anti-anxiety and relaxing.
CBG has been studied scientifically on a limited scale and needs to be examined further. However, studies by the National Center for Biotechnology Information thru the National Institute of Health, the Journal of Pharmacy and Pharmacology, and Science Direct, all point to the potential therapeutic benefits of CBG. CBG is non-psychoactive and appears to minimize the paranoia effects of THC. It appears to aid in the treatment of depression, inhibit the growth of tumors in colorectal cancer, alleviate the inflammation in persons suffering from Inflammatory Bowel Disease and Crohn’s Disease, relieve ocular pressure in patients suffering from glaucoma, assist in the treatment of bacterial infections including MRSA, minimize anxiety, protect neurons in patients suffering from Huntington’s disease which is characterized by nerve cell degeneration in the brain, and potentially assist in psoriasis and multiple sclerosis.
Please check out the following links on CBG and its potential health benefits: